Twist Bioscience Corporation Statistics
Share Statistics
Twist Bioscience Corporation has 59.36M shares outstanding. The number of shares has increased by 1.58% in one year.
Shares Outstanding | 59.36M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.62% |
Owned by Institutions (%) | n/a |
Shares Floating | 56.14M |
Failed to Deliver (FTD) Shares | 3.30K |
FTD / Avg. Volume | 0.45% |
Short Selling Information
The latest short interest is 9.02M, so 15.2% of the outstanding shares have been sold short.
Short Interest | 9.02M |
Short % of Shares Out | 15.2% |
Short % of Float | 16.02% |
Short Ratio (days to cover) | 15.97 |
Valuation Ratios
The PE ratio is -12.56 and the forward PE ratio is -18.87.
PE Ratio | -12.56 |
Forward PE | -18.87 |
PS Ratio | 8.38 |
Forward PS | 7.6 |
PB Ratio | 5.55 |
P/FCF Ratio | -37.89 |
PEG Ratio | n/a |
Enterprise Valuation
Twist Bioscience Corporation has an Enterprise Value (EV) of 960.09M.
EV / Earnings | -4.6 |
EV / Sales | 3.07 |
EV / EBITDA | -5.43 |
EV / EBIT | -4.35 |
EV / FCF | -13.88 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.03.
Current Ratio | 4.88 |
Quick Ratio | 4.54 |
Debt / Equity | 0.03 |
Total Debt / Capitalization | 3.04 |
Cash Flow / Debt | -4.33 |
Interest Coverage | -7614.86 |
Financial Efficiency
Return on equity (ROE) is -0.44% and return on capital (ROIC) is -39.7%.
Return on Equity (ROE) | -0.44% |
Return on Assets (ROA) | -0.34% |
Return on Capital (ROIC) | -39.7% |
Revenue Per Employee | 340.56K |
Profits Per Employee | -227.12K |
Employee Count | 919 |
Asset Turnover | 0.51 |
Inventory Turnover | 7.46 |
Taxes
Income Tax | 560.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 37.36% in the last 52 weeks. The beta is 1.78, so Twist Bioscience Corporation's price volatility has been higher than the market average.
Beta | 1.78 |
52-Week Price Change | 37.36% |
50-Day Moving Average | 44.83 |
200-Day Moving Average | 43.49 |
Relative Strength Index (RSI) | 50.99 |
Average Volume (20 Days) | 738.62K |
Income Statement
In the last 12 months, Twist Bioscience Corporation had revenue of $312.97M and earned -$208.73M in profits. Earnings per share was $-3.6.
Revenue | 312.97M |
Gross Profit | 133.35M |
Operating Income | -220.83M |
Net Income | -208.73M |
EBITDA | -176.71M |
EBIT | -220.83M |
Earnings Per Share (EPS) | -3.6 |
Balance Sheet
The company has $226.32M in cash and $85.03M in debt, giving a net cash position of $141.29M.
Cash & Cash Equivalents | 226.32M |
Total Debt | 85.03M |
Net Cash | 141.29M |
Retained Earnings | -1.24B |
Total Assets | 614.32M |
Working Capital | 275.77M |
Cash Flow
In the last 12 months, operating cash flow was -$64.09M and capital expenditures -$5.08M, giving a free cash flow of -$69.17M.
Operating Cash Flow | -64.09M |
Capital Expenditures | -5.08M |
Free Cash Flow | -69.17M |
FCF Per Share | -1.19 |
Margins
Gross margin is 42.61%, with operating and profit margins of -70.56% and -66.69%.
Gross Margin | 42.61% |
Operating Margin | -70.56% |
Pretax Margin | -66.51% |
Profit Margin | -66.69% |
EBITDA Margin | -56.46% |
EBIT Margin | -70.56% |
FCF Margin | -22.1% |
Dividends & Yields
TWST does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -7.57% |
FCF Yield | -2.45% |
Analyst Forecast
The average price target for TWST is $54.5, which is 14.6% higher than the current price. The consensus rating is "Buy".
Price Target | $54.5 |
Price Target Difference | 14.6% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Scores
Altman Z-Score | 11.85 |
Piotroski F-Score | 3 |